Nurix Therapeutics (NRIX) EBITDA (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of EBITDA data on file, last reported at -$94.2 million in Q2 2026.

• On a quarterly basis, EBITDA fell 94.95% year-over-year to -$94.2 million in Q2 2026; TTM through May 2026 was -$361.2 million, a 56.72% decrease from a year earlier, with the FY2025 full-year figure at -$285.7 million, down 34.1% from the prior year.
• EBITDA for Q2 2026 stood at -$94.2 million, down from -$92.5 million in the prior quarter.
• Over the last five years, EBITDA for NRIX reached as high as -$26.8 million in Q2 2023 and fell as low as -$94.2 million in Q2 2026.
• Historically, EBITDA has averaged -$56.9 million across 5 years, with a median of -$48.4 million in 2024.
• Across the five-year window, EBITDA jumped 41.45% in 2023 and slumped 94.95% in 2026, its largest moves.
• Year by year, EBITDA stood at -$48.7 million in 2022, then advanced by 6.89% to -$45.3 million in 2023, then plunged by 42.62% to -$64.7 million in 2024, then dropped by 28.52% to -$83.1 million in 2025, then slipped by 13.37% to -$94.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$94.2 million in Q2 2026, -$92.5 million in Q1 2026, and -$83.1 million in Q4 2025.